RE:RE:How does Accelerated Approval work Notwithstanding Merck's bispecific investment, Merck has its Keytruda franchise to protect, so is especially motivated to continue doing M&A deals to ring-fence its anti-PD-1 enterprise. The way forward is through the recently enacted IRA which provides novel biologics with 13 years of market exclusivity from the date of approval. So having ONCY's pelareorep combined with Merck's pelareorep in the treatment of breast or pancreatic cancer would give the soon-to-be off patent Keytruda another 13 years of exclusivity.
The same applies to other Big Pharma companies looking ro extend the life of their I/O blockbuster cancer products, and understand that combination I/O therapy is not only effective treatment but that acquiring companies with novel synergistic products, like ONCY's pelareorep, is the accelerated pathway to their oncology franchises' respective security.